中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages

文献类型：期刊论文

作者Chen, Mingshu1,2; Miao, Yunqiu2; Qian, Kun2; Zhou, Xin2; Guo, Linmiao2,3; Qiu, Yu2,3; Wang, Rui1; Gan, Yong2,3,4; Zhang, Xinxin2,3,5
刊名NANO LETTERS
出版日期2021-07-28
卷号21期号:14页码:6031-6041
关键词Immunochemotherapy triple-negative breast cancer liposomes tumor-associated macrophages MMP2 response
ISSN号1530-6984
DOI10.1021/acs.nanolett.1c01210
通讯作者Wang, Rui(ellewang@163.com) ; Gan, Yong(ygan@simro.ac.cn) ; Zhang, Xinxin(xinxinzhang@simm.ac.cn)
英文摘要Triple-negative breast cancer (TNBC) is an aggressive disease with a high recurrence rate and poor outcomes in clinic. In this study, inspired by the enriched innate immune cell type tumor-associated macrophages (TAMs) in TNBC, we proposed a matrix metalloprotease 2 (MMP2) responsive integrated immunochemotherapeutic strategy to deliver paclitaxel (PTX) and anti-CD47 (aCD47) by detachable immune liposomes (ILips). In the TNBC microenvironment, the "two-in-one" ILips facilitated MMP2-responsive release of aCD47 to efficiently polarize M2 macrophages toward the M1 phenotype to enhance phagocytosis against tumor cells and activate the systemic T cell immune response. Together with the immune effect, the detached PTX-loaded liposomes were internalized in MDA-MB-231 cells to synergistically inhibit tumor cell proliferation and metastasis. In the TNBC-bearing mouse model, PTX-loaded ILips demonstrated superior antitumor efficacy against TNBC and inhibited tumor recurrence. Our integrated strategy represents a promising approach to synchronously enhance immune response and tumor-killing effects, improving the therapeutic efficacy against TNBC.
WOS关键词POLARIZATION
资助项目National Natural Science Foundation of China[81973250] ; National Natural Science Foundation of China[82025032] ; Chinese Pharmacopoeia Commission[2021Y24] ; State Key Laboratory of Drug Research[SIMM2103ZZ-01] ; Major International Joint Research Project of Chinese Academy of Sciences[153631KYSB20190020]
WOS研究方向Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics
语种英语
WOS记录号WOS:000679930400017
出版者AMER CHEMICAL SOC
源URL[http://119.78.100.183/handle/2S10ELR8/297999]  
专题新药研究国家重点实验室
通讯作者Wang, Rui; Gan, Yong; Zhang, Xinxin
作者单位1.Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
4.Natl Inst Food & Drug Control, NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipi, Beijing 100050, Peoples R China
5.Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China
推荐引用方式
GB/T 7714		 Chen, Mingshu,Miao, Yunqiu,Qian, Kun,et al. Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages[J]. NANO LETTERS,2021,21(14):6031-6041.
APA Chen, Mingshu.,Miao, Yunqiu.,Qian, Kun.,Zhou, Xin.,Guo, Linmiao.,...&Zhang, Xinxin.(2021).Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages.NANO LETTERS,21(14),6031-6041.
MLA Chen, Mingshu,et al."Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages".NANO LETTERS 21.14(2021):6031-6041.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。